Comparative evaluation of various prostate specific antigen ratios for the early detection of prostate cancer

BJU International

Volumn 93, Issue 7, 2004, Pages 970-974

  Ozdal, O L ^a   Aprikian, A G ^a   Begin L R ^a   Behlouli, H ^a   Tanguay, S ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Detection; Free PSA; Prostate cancer; PSA ratio

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER RISK; CANCER SCREENING; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; EARLY DIAGNOSIS; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; TRANSRECTAL ULTRASONOGRAPHY; ARTICLE; BLOOD; EVALUATION; PROSTATE TUMOR; SENSITIVITY AND SPECIFICITY;

EARLY DIAGNOSIS; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 2942542646     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2003.04762.x     Document Type: Conference Paper

References (28)

1. Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen. A decade of discovery - what we have learned and where we are going. J Urol 1999; 162: 293-306
2. 1-1-chimotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991; 51: 222-6
3. 1-antichymotrypsin. Clin Chem 1991; 37: 1618-25
4. McCormack RT, Rittenhouse HG, Finley JA et al. Molecular forms of prostate-specific antigen and the human kallikrein family: a new era. Urology 1995; 45: 729-44
5. Benson MC, Whang IS, Pantuck A et al. Prostate-specific antigen density. A means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 1992; 147: 815-6
6. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987; 317: 909-16
7. Zlotta AR, Djavan B, Marberger M, Schulman CC. Prostate-specific antigen density of the transition zone: a new effective parameter for prostate cancer prediction. J Urol 1997; 157: 1315-21
8. Carter HB, Pearson JD, Metter EJ et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992; 267: 2215-20
9. Oesterling JE, Jacobsen SJ, Chute CG et al. Serum prostate-specific antigen in community-based population of healthy men. Establishment of age specific reference ranges. JAMA 1993; 270: 860-4
10. Littrup PJ, Kane RA, Mettlin G et al. Cost-effective prostate cancer detection. Reduction in low yield biopsies. Cancer 1994; 74: 3146-58
11. Partin AW, Catalona WJ, Southwick PC, Subong ENP, Gasior GH, Chan DW. Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: Influence of total PSA, prostate volume, and age. Urology 1996; 48 (Suppl. 6A): 55-61
12. Luderer AA, Chen YT, Soriano TF et al. Measurement of the proportion free total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urology 1995; 46: 187-94
13. Catalona WJ, Smith DS, Wolfert RL et al. Evaluation of percentage free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 1995; 274: 1214-20
14. 1-antichymotrypsin production in PSA producing cells is common in prostate cancer but rare in benign prostatic hyperplasia. Urology 1994; 43: 427-34
15. Brawer MK, Cheli CD, Neaman IE et al. Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. J Urol 2000; 163: 1476-80
16. Mitchell IDC, Croal BL, Chen DNP, Ross I. A prospective study to evaluate the role of prostate specific antigen and free/total prostate specific antigen ratio for the diagnosis of prostate cancer. J Urol 2001; 165: 1549-53
17. Brawer MK, Meyer GE, Letran JL et al. Measurement of complexed PSA improves specificity for early detection of prostate cancer. Urology 1998; 52: 372-8
18. Tanguay S, Begin LR, Elhilali MM, Behlouli H, Karakiewicz PI, Aprikian AG. Comparative evaluation of total PSA, free/total PSA, and complexed PSA in prostate cancer detection. Urology 2002; 59: 261-5
19. Karakiewicz PI, Bazinet M, Aprikian AG et al. Outcome of the sextant biopsy according to gland volume. Urology 1997; 49: 55-9
20. Catalona WJ. Clinical utility of measurements of free and total prostate-specific antigen (PSA): a review. Prostate Supplement: 1996; 7: 64-9
21. Lein M, Jung K, Elgeti U et al. Ratio of alpha 1-chymotrypsin-prostate specific antigen to total prostate specific antigen in prostate cancer diagnosis. Anticancer Res 2000; 20: 4997-5001
22. Ogekawa T, Kinjo K, Watanabe K et al. The significance of the free-to-complexed prostate-specific antigen (PSA) ratio in prostate cancer detection in patients with a PSA level of 4.1-10 ng/mL. BJU Int 2000; 85: 708-14
23. Maeda H, Arai Y, Aoki Y, Okubo K, Okada T, Maekawa S. Complexed prostate specific antigen and its volume indexes in the detection of prostate cancer. Urology 1999; 54: 225-8
24. 1-antichymotrypsin-prostate-specific antigen in prostate cancer diagnosis. Prostate 2001; 47: 77-84
25. Okihara K, Fritsche H, Ayala A, Johnston AD, Allard WJ, Babaian RJ. Can complexed prostate specific antigen and prostatic volume enhance prostate cancer detection in men with total prostate specific antigen between 2.5 and 4.0 ng/ml. J Urol 2001; 165: 1930-6
26. Jung K, Elgeti U, Lein M et al. Ratio of free or complexed prostate-specific antigen (PSA) to total PSA. Which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer? Clin Chem 2000; 46: 55-62
27. Egawa S, Suyama K, Matsumoto K, Kuwao S, Baba S. Prospective evaluation of prostate cancer detection by prostate specific antigen related parameters: Comparison in serum and plasma samples. J Urol 2002; 167: 97-102
28. Naughton CK, Miller DC, Mager DE, Ornstein DK, Catalona WJ. A prospective randomized trial comparing 6 versus 12 prostate biopsy cores. impact on cancer detection. J Urol 2000; 164: 388-92